0001104659-21-090300.txt : 20210708
0001104659-21-090300.hdr.sgml : 20210708
20210708171617
ACCESSION NUMBER: 0001104659-21-090300
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210707
FILED AS OF DATE: 20210708
DATE AS OF CHANGE: 20210708
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gad Thomas
CENTRAL INDEX KEY: 0001753224
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38650
FILM NUMBER: 211080954
MAIL ADDRESS:
STREET 1: C/O Y-MABS THERAPEUTICS, INC.
STREET 2: 230 PARK AVENUE, 33RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10169
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Y-mAbs Therapeutics, Inc.
CENTRAL INDEX KEY: 0001722964
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474619612
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 750 THIRD AVENUE
STREET 2: 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10017
BUSINESS PHONE: 212-847-9841
MAIL ADDRESS:
STREET 1: 750 THIRD AVENUE
STREET 2: 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10017
4
1
tm2121612-2_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-07-07
0
0001722964
Y-mAbs Therapeutics, Inc.
YMAB
0001753224
Gad Thomas
C/O Y-MABS THERAPEUTICS, INC.
230 PARK AVENUE, SUITE 3350
NEW YORK
NY
10169
1
1
0
0
See remarks
Common Stock
2021-07-07
4
S
0
4000
31.8662
D
1591927
I
By GAD Enterprises LLC
Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2021.
This transaction was executed in multiple trades at prices ranging from $31.36 to $32.59. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.
Chairman, President and Head of Business Development & Strategy
/s/ THOMAS GAD
2021-07-08